Across TCGA pan-cancer cohorts, METTL9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated METTL9 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher METTL9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL9 expression acts as an unfavorable survival marker.

STAD, LUAD, and PRAD are the cancer types where METTL9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.003	0.660	<.001	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: METTL9 tumor-vs-normal RNA expression · all METTL9 data types